$4.4 Billion Global Autoimmune Disease Diagnosis Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Autoimmune Disease Diagnosis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

The global autoimmune disease diagnosis market reached a value of US$ 4.4 Billion in 2020. Looking forward, the publisher expects the global autoimmune disease diagnosis market to grow at a CAGR of 8.10% during 2021-2026.

An autoimmune disease refers to a condition wherein the immune system attacks and destroys healthy cells, tissues, and organs of the body. In the longer run, it can also lead to abnormal growth of an organ and changes in organ function. Currently, more than 80 different autoimmune disorders have been identified by scientists, out of which Systemic Lupus Erythematosus (SLE), multiple sclerosis, rheumatoid arthritis, and type I diabetes, are the most common. Depending on the disorder, the doctor uses a combination of methods, which include a physical examination, medical history, blood tests, biopsy, and X-rays, to provide an effective diagnosis. They prescribe anti-inflammatory and immunosuppressant drugs, physical therapy, surgery, and injections, to control the overactive immune response and provide relief from symptoms.

Owing to the rising prevalence of autoimmune diseases, healthcare professionals around the world are focusing on the adoption of advanced technologies to conduct multiple tests with faster and more precise results. Apart from this, a large number of research and diagnostics institutes are undertaking public awareness campaigns to educate individuals about autoimmune diseases and their possible treatments and diagnosis, which is positively influencing the market growth. Furthermore, several governing authorities, along with non-governing organizations, are funding various programs to develop novel therapeutics.

For instance, the AMP RA/SLE Program, launched by the Accelerating Medicines Partnership (AMP), is a public-private partnership between the National Institutes of Health (NIH), the US Food and Drug Administration (FDA) and multiple non-profit organizations. The program aims to identify relevant drug targets for the treatment of autoimmune diseases.

Companies Mentioned

• Abbott Laboratories
• Aesku.Diagnostics GmbH & Co. KG
• Beckman Coulter Inc. (Danaher Corporation)
• bioMerieux SA (Institut Merieux)
• Bio-Rad Laboratories Inc.
• Euroimmun AG (PerkinElmer Inc.)
• Hemagen Diagnostics Inc.
• Inova Diagnostics Inc. (Werfen Group S.A.)
• Myriad Genetics Inc.
• Quest Diagnostics Incorporated
• Siemens Healthineers AG (Siemens AG)
• SQI Diagnostics
• Thermo Fisher Scientific Inc.
• Trinity Biotech

Key Questions Answered in This Report:

• How has the global autoimmune disease diagnosis market performed so far and how will it perform in the coming years?
• What are the key regional markets?
• What has been the impact of COVID-19 on the global autoimmune disease diagnosis market?
• What is the breakup of the market based on the product type?
• What is the breakup of the market based on the disease type?
• What is the breakup of the market based on the test type?
• What is the breakup of the market based on the end-user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global autoimmune disease diagnosis market and who are the key players?
• What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Autoimmune Disease Diagnosis Market

5.1 Market Overview

5.2 Market Performance

5.3 Impact of COVID-19

5.4 Market Forecast

6 Market Breakup by Product Type

6.1 Consumables and Assay Kits

6.1.1 Market Trends

6.1.2 Market Forecast

6.2 Instruments

6.2.1 Market Trends

6.2.2 Market Forecast

7 Market Breakup by Disease Type

7.1 Systemic Autoimmune Disease

7.1.1 Market Trends

7.1.2 Market Breakup by Type

7.1.2.1 Rheumatoid Arthritis

7.1.2.2 Psoriasis

7.1.2.3 Systemic Lupus Erythematosus (SLE)

7.1.2.4 Multiple Sclerosis

7.1.2.5 Others

7.1.3 Market Forecast

7.2 Localized Autoimmune Disease

7.2.1 Market Trends

7.2.2 Market Breakup by Type

7.2.2.1 Inflammatory Bowel Disease

7.2.2.2 Type 1 Diabetes

7.2.2.3 Thyroid

7.2.2.4 Others

7.2.3 Market Forecast

8 Market Breakup by Test Type

8.1 Routine Laboratory Tests

8.1.1 Market Trends

8.1.2 Market Forecast

8.2 Inflammatory Markers

8.2.1 Market Trends

8.2.2 Market Forecast

8.3 Autoantibodies and Immunologic Tests

8.3.1 Market Trends

8.3.2 Market Forecast

8.4 Others

8.4.1 Market Trends

8.4.2 Market Forecast

9 Market Breakup by End-User

9.1 Clinical Laboratories

9.1.1 Market Trends

9.1.2 Market Forecast

9.2 Hospitals

9.2.1 Market Trends

9.2.2 Market Forecast

9.3 Others

9.3.1 Market Trends

9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America

10.2 Asia Pacific

10.3 Europe

10.4 Latin America

10.5 Middle East and Africa

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Competitive Landscape

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

For more information about this report visit https://www.researchandmarkets.com/r/a694gm